[1] Roodman G D. Pathogenesis of myeloma bone disease[J]. Leukemia, 2009,23(3):435-441.
[2] Guzik G. Oncological and functional results of the surgical treatment of vertebral metastases in patients with multiple myeloma"[J]. BMC Surg, 2017,17(1):92.
[3] Frassica F J, Frassica D A. Evaluation and treatment of metastases to the humerus[J]. Clin Orthop Relat Res, 2003(415 Suppl):S212-S218.
[4] Weiss K R, Bhumbra R, Biau D J, et al. Fixation of pathological humeral fractures by the cemented plate technique[J]. J Bone Joint Surg Br, 2011,93(8):1093-1097.
[5] Laitinen M, Nieminen J, Pakarinen T K. Treatment of pathological humerus shaft fractures with intramedullary nails with or without cement fixation[J]. Arch Orthop Trauma Surg, 2011,131(4):503-508.
[6] Camnasio F, Scotti C, Peretti G M, et al. Prosthetic joint replacement for long bone metastases: analysis of 154 cases[J]. Arch Orthop Trauma Surg, 2008,128(8):787-793.
[7] Capanna R, Campanacci D A. The treatment of metastases in the appendicular skeleton[J]. J Bone Joint Surg Br, 2001,83(4):471-481.
[8] Sarahrudi K, Wolf H, Funovics P, et al. Surgical treatment of pathological fractures of the shaft of the humerus[J]. J Trauma, 2009,66(3):789-794.
[9] Atesok K, Liebergall M, Sucher E, et al. Treatment of pathological humeral shaft fractures with unreamed humeral nail[J]. Ann Surg Oncol, 2007,14(4):1493-1498.
[10] Rajkumar S V, Dimopoulos M A, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J]. Lancet Oncol, 2014,15(12):e538-e548.
[11] Landgren O, Weiss B M. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis[J]. Leukemia, 2009,23(10):1691-1697.
[12] Landgren O, Graubard B I, Katzmann J A, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey[J]. Leukemia, 2014,28(7):1537-1542.
[13] Chavda S J, Yong K. Multiple myeloma[J]. Br J Hosp Med (Lond), 2017,78(2):C21-C27.
[14] Landgren O, Kyle R A, Pfeiffer R M, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study[J]. Blood, 2009,113(22):5412-5417.
[15] Weiss B M, Abadie J, Verma P, et al. A monoclonal gammopathy precedes multiple myeloma in most patients[J]. Blood, 2009,113(22):5418-5422.
[16] Kyle R A, Therneau T M, Rajkumar S V, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance[J]. N Engl J Med, 2002,346(8):564-569.
[17] Kyle R A, Larson D R, Therneau T M, et al. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance[J]. N Engl J Med, 2018,378(3):241-249.
[18] Terpos E, Morgan G, Dimopoulos M A, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease[J]. J Clin Oncol, 2013,31(18):2347-2357.
[19] Terpos E, Berenson J, Cook R J, et al. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease[J]. Leukemia, 2010,24(5):1043-1049.
[20] Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Pathogenesis of bone disease in multiple myeloma: from bench to bedside[J]. Blood Cancer J, 2018,8(1):7.
[21] Dimopoulos M A, Jakubowiak A J, McCarthy P L, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma[J]. Blood Cancer J, 2020,10(2):17.
[22] Lakshman A, Paul S, Rajkumar S V, et al. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance[J]. Leukemia, 2018,32(8):1811-1815.
[23] Chawla S S, Kumar S K, Dispenzieri A, et al. Clinical course and prognosis of non-secretory multiple myeloma[J]. Eur J Haematol, 2015,95(1):57-64.
[24] Hillengass J, Usmani S, Rajkumar S V, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders[J]. Lancet Oncol, 2019,20(6):e302-e312.
[25] Takei T, Coles M. Treatment of pathologic fracture and surgical value of prognostic factors in multiple myeloma[J]. Int Surg, 1996,81(4):403-406.
[26] Durr H R, Kuhne J H, Hagena F W, et al. Surgical treatment for myeloma of the bone. A retrospective analysis of 22 cases[J]. Arch Orthop Trauma Surg, 1997,116(8):463-469.
[27] Choi E, Han I, Cho H S, et al. Intramedullary Nailing for Pathological Fractures of the Proximal Humerus[J]. Clinics in Orthopedic Surgery, 2016,8(4):458.
[28] Kehrer M, Koob S, Kehrer A, et al. Multiple Myeloma - Current Standards in Surgical Treatment[J]. Z Orthop Unfall, 2019,157(2):164-172.
[29] Siegel H J, Lopez-Ben R, Mann J P, et al. Pathological fractures of the proximal humerus treated with a proximal humeral locking plate and bone cement[J]. J Bone Joint Surg Br, 2010,92(5):707-712.
[30] Bickels J, Kollender Y, Wittig J C, et al. Function after resection of humeral metastases: analysis of 59 consecutive patients[J]. Clin Orthop Relat Res, 2005(437):201-208.
[31] Piccioli A, Maccauro G, Rossi B, et al. Surgical treatment of pathologic fractures of humerus[J]. Injury, 2010,41(11):1112-1116.
[32] Karataglis D, Stavridis S I, Petsatodis G, et al. New trends in fixation of proximal humeral fractures: a review[J]. Injury, 2011,42(4):330-338.
[33] Young A A, Hughes J S. Locked intramedullary nailing for treatment of displaced proximal humerus fractures[J]. Orthop Clin North Am, 2008,39(4):417-428.
[34] Dijkstra S, Stapert J, Boxma H, et al. Treatment of pathological fractures of the humeral shaft due to bone metastases: a comparison of intramedullary locking nail and plate osteosynthesis with adjunctive bone cement[J]. Eur J Surg Oncol, 1996,22(6):621-626.
[35] Vaishya R, Vijay V, Agarwal A K. Healing of pathological fracture in a case of multiple myeloma[J]. BMJ Case Rep, 2017,2017.
[36] Thai D M, Kitagawa Y, Choong P F. Outcome of surgical management of bony metastases to the humerus and shoulder girdle: a retrospective analysis of 93 patients[J]. Int Semin Surg Oncol, 2006,3:5.